All In Biotech

Drug Trial Radar · NCT06620692

A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis

A Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Xantho Biotechnology Co., LTDIndustry
Sponsor type
Industry
Collaborators
Virginia Contract Research Organization Co., Ltd.
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase IIa clinical trial. Around 65 subjects will be enrolled into this study to primarily assess the treatment efficacy of 5% GM-XANTHO in patients with psoriasis, as well as the safety and tolerability of 5% GM-XANTHO. Two third of the total subjects will be given the investigational product, 5% GM-XANTHO, and the other third will take placebo. The treatment period will last for 28 consecutive days, followed by a safety follow-up for 2 weeks. During the study, there will be 8 scheduled visits to the clinical center.

Conditions

  • Psoriasis

Interventions

  • 5% GM-XANTHO [GM-XAN003]Drug

    5% GM-XANTHO \[GM-XAN003\]

  • PlaceboDrug

    The placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Psoriasis Area and Severity Index (PASI)Time frame: through study completion, an average of 7 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.